Healthcare Triangle is registering 28,000,000 shares of common stock for resale, against a base of 2,027,783 shares outstanding as of July 8, 2026 (S-1 The Offering). The Company's founder holds 20,000 shares of Series A Super Voting Preferred Stock, each entitled to 1,000 votes per share, issued to him in two tranches in July 2021 and March 2025 (S-1).

Healthcare Triangle, Inc. is a Pleasanton, California healthcare information technology company providing cloud, data science, and managed services to healthcare and life sciences customers (S-1 Prospectus Summary). Its common stock trades on the Nasdaq Capital Market under the symbol HCTI; the last reported close on July 8, 2026 was $1.70 (S-1 cover). On July 10, 2026, the Company filed an S-1 to register 28,000,000 shares issuable under an Equity Line of Credit signed June 12, 2026 with Hudson Global Ventures, LLC (S-1 The Offering).

The origin story

Healthcare Triangle was incorporated in Nevada on October 29, 2019 and converted to a Delaware corporation on April 24, 2020 (S-1 Prospectus Summary). Its business commenced on January 1, 2020 after SecureKloud Technologies Inc. transferred its Life Sciences business to the Company (S-1).

On October 21, 2024, the Company entered into an Asset Transfer Agreement with SecureKloud Technologies, Inc. and acquired substantially all of SecureKloud's cloud and technology business, issuing 1,600,000 shares of Series B Convertible Preferred Stock at $4.50 per share, valuing the transferred assets at $7.2 million (S-1).

On February 10, 2026, the Company effected a 1-for-60 reverse stock split of all issued and outstanding common shares (S-1 Recent Developments).

On January 22, 2026 (as amended June 25, 2026), the Company entered into a Share Purchase Agreement to acquire Teyame Holdings Inc. and its Spanish operating entities Teyamé 360 S.L. and Datono Mediación S.L. for consideration of up to $50 million: cash of up to $15 million, $12 million in common stock, $18 million in convertible preferred stock, plus an earnout component (S-1 Recent Developments).

The people running it

Suresh Venkatachari is the Company's Founder and the sole holder of its Series A Super Voting Preferred Stock (S-1). He received 6,000 Series A Super Voting Preferred Shares on July 12, 2021 and an additional 14,000 shares on March 12, 2025, both issuances made pursuant to the terms of his employment agreement (S-1). His active operating role is disclosed as President & CEO of SecureKloud Technologies Limited, where he holds approximately 42% of voting rights (10-K/A).

David Ayanoglou has served as Chief Financial Officer since April 9, 2025 (10-K/A). He is identified in the filing as key management personnel and a chief operating decision maker.

Sujatha Ramesh was appointed Chief Operating Officer effective March 18, 2025 and Executive Board Director effective April 10, 2025 (10-K/A).

Dave Rosa serves as Independent Chairman of the Board (10-K/A). Jainal Bhuiyan chairs the Nominating and Corporate Governance Committee and sits on the Audit Committee. Ron McClurg chairs the Audit Committee and sits on the Compensation and Nominating and Corporate Governance Committees (10-K/A).

Hudson Global Ventures, LLC, the Selling Stockholder, is at 1 Linden Place, Suite 210, Great Neck, NY 11021; Seth Ahdoot and Soheil Ahdoot have voting and investment control (S-1 Selling Stockholder).

By the numbers

  • FY 2025 net revenue: $13.9 million, up 19% from $11.7 million in FY 2024 (10-K/A Segments)
  • FY 2025 gross margin: 13.6%, down from 24.7% in FY 2024 (a decline of 11 percentage points on revenue that grew 19%) (10-K/A)
  • FY 2025 operating loss: $9.1 million, widened from a $3.9 million operating loss in FY 2024 (10-K/A)
  • FY 2025 net loss: $9.5 million, up from $6.0 million in FY 2024 (10-K/A)
  • Cash at December 31, 2025: $7.6 million, up from $20 thousand at year-end 2024 (10-K/A Balance Sheet)
  • Top five customers accounted for 58% of FY 2025 revenue; the single largest customer accounted for 20% (10-K/A)
  • Common shares outstanding as of July 8, 2026: 2,027,783, reflecting the 1-for-60 reverse split effected February 10, 2026 (S-1 The Offering)
  • Weighted average exercise price on outstanding warrants (24,765 shares underlying): $509.05, against the $1.70 last-reported close on July 8, 2026 (S-1 The Offering)
  • ELOC Warrant exercise price: $0.00001 per share (S-1 Risk Factors)

What could break

Dilution scale. The 28,000,000 shares being registered represent nearly 14 times the 2,027,783 common shares outstanding on July 8, 2026 (S-1 The Offering). The Risk Factors state directly that sales to the Selling Stockholder "could result in substantial dilution to the interests of other holders of our common stock" (S-1 Risk Factors).

Super-voting overhang. The 20,000 Series A Super Voting Preferred shares held by the Founder carry 20,000,000 votes at 1,000 votes per share, against 2,027,783 common shares carrying one vote each (S-1). Even after the full 28,000,000-share ELOC issuance, the Series A super-voting block remains a controlling majority of votes.

Customer concentration. In FY 2025, the top five customers accounted for approximately 58% of revenue and the single largest customer for approximately 20% (10-K/A).

The offering

This is a resale registration under an Equity Line of Credit, not a primary underwritten offering. The S-1 registers 28,000,000 shares of Common Stock: up to 27,950,000 shares issuable under the ELOC Purchase Agreement dated June 12, 2026, plus 50,000 shares issuable under the ELOC Warrant issued as a commitment fee at an exercise price of $0.00001 per share (S-1 The Offering). Common shares outstanding immediately after the offering, assuming full ELOC issuance and warrant exercise: 30,027,783 (S-1 The Offering). The Company receives no proceeds from the resale and may receive up to $50.0 million by directing sales to Hudson Global Ventures over a 36-month period beginning after certain conditions are met (S-1 The Offering). The Selling Stockholder is deemed an "underwriter" within the meaning of Section 2(a)(11) of the Securities Act with respect to the resale of the shares (S-1). No traditional book-running underwriter is listed.

What to watch

  • ELOC 36-month term: the ELOC Purchase Agreement's 36-month sales window begins after satisfaction of certain conditions following the June 12, 2026 signing (S-1 Risk Factors).
  • Teyame acquisition payments: cash consideration includes $6.0 million due by January 29, 2026, $3.0 million due April 29, 2026, and $3.0 million contingent on the Intermediary Seller obtaining certain VAT clearances and change-of-control waivers (S-1 Recent Developments).
  • Teyame preferred conversion: $18.0 million preferred stock component convertible into 7,743,687 shares of Common Stock upon applicable shareholder approval (S-1 Recent Developments).
  • Series B Preferred conversion: 1,600,000 shares of Series B Convertible Preferred Stock convertible into 10 common shares each, subject to shareholder approval (S-1).
  • Convertible Notes: on June 12, 2026 the Company issued 15% original issue discount senior convertible promissory notes with aggregate principal of $4.235 million for approximately $3.6 million in net proceeds (S-1 Recent Developments).

Sources

Not financial advice.